You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Electronic Image Trial Management System

    SBC: VIRTUALSCOPICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Delays in FDA drug approval are measured in lost lives (estimated to be hundreds of thousands over the last few decades) and increased costs to U.S. citizens for drugs that are eventually approved. One factor contributing to the delay in drug approvals is the widespread use of time-consuming and error-prone manual methods to deliver medical images (i.e. CT, MR, ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  2. Lactoferrin Enhances Growth and Reduces Nosocomial Infection in Preterm Infants

    SBC: AGENNIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This project aims to develop talactoferrin (TLF, recombinant human lactoferrin) as a therapeutic agent to treat prematurely born neonates. The treatment will be given orally shortly after birth to prevent nosocomial infections (NIs) due to abnormal bacterial invasion of neonatal intestinal epithelia and consequently to limit systemic bacteremia and necrotizing ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  3. Cardiac Regenerative Therapy with Cyclin A2

    SBC: VentriNova, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The morbidity and mortality due to cardiovascular disease is attributed to the lack of significant replicative potential of adult mammalian cardiomyocytes. Thus myocyte loss in response to ischemic injury typically results in scar formation and a decline of cardiac function that is usually irreversible. The cessation of myocyte proliferation is associated with ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  4. Optimize RNA-aptamer for Biomarker Molecule CD30

    SBC: AM BIOTECHNOLOGIES, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Systemic Anaplastic Large Cell Lymphoma (ALCL) is the most common T-cell lymphoma in children. ALCL is characterized by its anaplastic cell morphology and high level expression of CD30 on the cell surface. This diffuse and homogeneous CD30 expression in ALCL cells and tumors has been considered as a diagnostic feature for the disease and anti-CD30 antibodies ar ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  5. Single molecule fluorescence detection of fragile X mutations

    SBC: AMBION DIAGNOSTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Fragile X Syndrome (FXS), is the most common form of inherited mental retardation, affecting 1 in 4000 males and about 1 in 6000 females of all ethnicities. Additionally, carrier frequencies are quite high. About 1 in 250 females carry Fragile X and about 1 in 800 men carry Fragile X. FXS was one of the first human diseases to be linked to an expansion of trip ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  6. Amplification Strategies for Detection of Fragile X Trinucleotide Repeats

    SBC: AMBION DIAGNOSTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The overall objective for this project is to develop and implement a comprehensive set of technologies to improve screening and diagnosis of conditions associated with Fragile X Syndrome (FXS). FXS is caused by an expansion of a cytosine-guanine-guanine (CGG) triplet repeat in the 5'-untranslated region of the FMR1 gene. FXS affects 1/4000 men and 1/6000 women ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  7. MicroRNA Markers of Melanoma Metastasis in Lymph Nodes

    SBC: AMBION DIAGNOSTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Malignant melanoma is the least frequent but the most aggressive and deadliest form of skin cancer. Early detection and accurate staging are therefore crucial to ensure timely intervention and a good prognosis. Our long-term goal is to develop a microRNA (miRNA) -based assay for the accurate staging of cutaneous malignant melanoma. To accomplish this goal, we w ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  8. Identification of microRNA Biomarkers for Lung Cancer

    SBC: AMBION DIAGNOSTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): In the United States, lung cancer has the highest incidence and the highest mortality rate of all cancers. An estimated 215,020 new cases of lung cancer and an estimated 161,840 deaths from lung cancer will occur in the United States during 2008. This high mortality rate of lung cancer has been attributed in part to the fact that majority (gt75%) of the patient ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  9. Multiplex Detection of Mutations in Leukemia Patients

    SBC: AMBION DIAGNOSTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term objective of this project is to develop a comprehensive molecular diagnostic assay for the detection of clinically relevant genetic abnormalities in patients with acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), and myeloproliferative disorders (MPDs). An estimated 44,000 new leukemia cases were predicted for 2008, with more than ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  10. RNA Amplification for Diagnostic Microarrays

    SBC: AMBION DIAGNOSTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this proposal is to develop and implement an integrated suite of technologies for enabling microarray-based diagnostic assays and the cGMP manufacturing processes and procedures necessary to manufacture these products. Microarrays have found widespread use in biology and medicine as important tools for evaluating gene expression and genomics ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government